Clinical Trials
3 trialsNCT04855136 2025-09-11
KarMMa-7
Celgene
Phase 1/2 Terminated
NCT04464798 2025-04-29
A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas
Celgene
Phase 1 Terminated
NCT05289492 2024-10-26
Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma
iTeos Therapeutics
Phase 1 Terminated